What's Happening?
Faruqi & Faruqi LLP, a national securities law firm, is investigating claims against ADMA Biologics, Inc. and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges
that ADMA Biologics and its executives violated federal securities laws by making false and misleading statements and failing to disclose key information. Specifically, the complaint claims that ADMA engaged in an undisclosed related-party transaction, used channel stuffing to create the appearance of stronger revenue growth, and lacked adequate internal controls. These actions allegedly rendered the company's public statements about its operations and financial performance misleading. The lawsuit follows a report by Culper Research, which revealed that ADMA Biologics induced a distributor to stock excess ASCENIV, allowing the company to report growth that was not actually there.
Why It's Important?
The class action lawsuit against ADMA Biologics highlights significant concerns about corporate governance and transparency in the biotech industry. If the allegations are proven, it could lead to substantial financial repercussions for the company and its investors. The case underscores the importance of accurate financial reporting and the potential consequences of misleading investors. For shareholders, the lawsuit represents an opportunity to seek redress for losses incurred due to the alleged misconduct. The outcome of this case could also influence regulatory scrutiny and compliance standards within the industry, potentially leading to more stringent oversight of financial practices.
What's Next?
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, are encouraged to review their transaction records and consider their legal options. The deadline to seek appointment as lead plaintiff is August 10, 2026. Faruqi & Faruqi LLP is actively seeking information from whistleblowers, former employees, and shareholders to strengthen the case. The firm is also conducting an independent market study to assess the impact of the alleged misconduct on ADMA Biologics' market position and investor confidence.
